Union Korea Pharm Cuts Capital by 0.3% Through Cancellation of 243,338 Shares

• Union Korea Pharm announced on Oct. 21, 2026, a capital reduction canceling 243,338 ordinary shares, representing 0.3% of outstanding shares.
• The transaction involves a three-for-one consolidation of 365,003 ordinary shares issued through a debt-to-equity conversion.
• Outstanding ordinary shares will decrease to 79,972,918 from 80,216,256.
• Capital will decline to KRW 39.99 billion from KRW 40.11 billion.
• Fractional shares arising from the consolidation will be canceled without compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Union Korea Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021000092), on October 21, 2026, and is solely responsible for the information contained therein.